综述

HIV感染/AIDS合并结核病的临床及免疫学特点研究进展

展开
  • 复旦大学附属公共卫生临床中心感染与免疫科,上海 201508

收稿日期: 2021-03-20

  网络出版日期: 2022-06-28

基金资助

“十三五”国家科技重大专项(2017ZX10202101);上海市科委项目:上海市感染性疾病(艾滋病)临床医学研究中心(20MC1920100);上海市传染病临床重点专科项目(shslczdzk01102);上海市科委医学创新研究专项重大项目(21Y30900400)

本文引用格式

郭静, 沈银忠 . HIV感染/AIDS合并结核病的临床及免疫学特点研究进展[J]. 诊断学理论与实践, 2021 , 20(04) : 401 -406 . DOI: 10.16150/j.1671-2870.2021.04.014

参考文献

[1] Jilani TN, Avula A, Zafar Gondal A, et al. Active tuberculosis[M]. StatPearls. Treasure Island (FL): StatPearls, 2020.
[2] 中华医学会感染病学分会艾滋病学组, 中华医学会热带病与寄生虫学分会艾滋病学组. HIV合并结核分枝杆菌感染诊治专家共识[J]. 中华临床感染病杂志, 2017,10(2):81-90.
[3] World Health Organization. Global tuberculosis reports[EB/OL]. 2021-01-14[2021-03-03]. https://www.who.int/tb/publications/global_report/en/.
[4] World Health Organization. HIV/AIDS[EB/OL]. 2021-01-14[2021-03-03]. https://www.who.int/news-room/fact-sheets/detail/hiv-aids.
[5] 中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2018版)[J]. 新发传染病电子杂志, 2019,4(2):65-84.
[6] Bruchfeld J, Correia-Neves M, Kllenius G. Tuberculosis and HIV coinfection[J]. Cold Spring Harb Perspect Med, 2015,5(7):a017871.
[7] World Health Organization. Tuberculosis and HIV[EB/OL]. 2021-01-14[2021-03-03]. https://www.who.int/hiv/topics/tb/en/.
[8] Montales MT, Chaudhury A, Beebe A, et al. HIV-associated TB syndemic: a growing clinical challenge worldwide[J]. Front Public Health, 2015,3:281.
[9] Gupta RK, Lucas SB, Fielding KL, et al. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis[J]. AIDS, 2015,29(15):1987-2002.
[10] GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet,2018, 392(10159):1736-1788.
[11] Bisson GP, Bastos M, Campbell JR, et al. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis[J]. Lancet, 2020,396(10248):402-411.
[12] Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Di-seases Society of America[EB/OL]. 2020-06-29[2021-08-19].
[13] Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings[J]. Lancet Infect Dis, 2009,9(3):173-184.
[14] Rajasekaran S, Mahilmaran A, Annadurai S, et al. Manifestation of tuberculosis in patients with human immuno-deficiency virus: a large Indian study[J]. Ann Thorac Med, 2007,2(2):58-60.
[15] Méndez-Samperio P. Diagnosis of Tuberculosis in HIV Co-infected Individuals: Current Status, Challenges and Opportunities for the Future[J]. Scand J Immunol, 2017,86(2):76-82.
[16] Manosuthi W, Wiboonchutikul S, Sungkanuparph S. Integrated therapy for HIV and tuberculosis[J]. AIDS Res Ther, 2016,13:22.
[17] Scott L, da Silva P, Boehme CC, et al. Diagnosis of opportunistic infections: HIV co-infections - tuberculosis[J]. Curr Opin HIV AIDS, 2017,12(2):129-138.
[18] Denkinger CM, Schumacher SG, Boehme CC, et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis[J]. Eur Respir J, 2014,44(2):435-446.
[19] de Siqueira-Filha NT, Legood R, Cavalcanti A, et al. Cost of Tuberculosis diagnosis and treatment in patients with HIV: a systematic literature review[J]. Value Health, 2018,21(4):482-490.
[20] Abay SM, Deribe K, Reda AA, et al. The effect of early initiation of antiretroviral therapy in TB/HIV-coinfected patients: a systematic review and meta-analysis[J]. J Int Assoc Provid AIDS Care, 2015,14(6):560-570.
[21] Lackner AA, Lederman MM, Rodriguez B. HIV pathogenesis: the host[J]. Cold Spring Harb Perspect Med, 2012,2(9):a007005.
[22] Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease[J]. Annu Rev Pathol, 2011,6:223-248.
[23] Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners[J]. J Infect Dis, 2005,191(2):150-158.
[24] Du Bruyn E, Wilkinson RJ. The immune interaction between HIV-1 Infection and Mycobacterium tuberculosis[J/OL]. Microbiol Spectr, 2016[2021-03-03]. https://pubmed.ncbi.nlm.nih.gov/28084192/.
[25] Manabe YC, Andrade BB, Gupte N, et al. A Parsimonious host inflammatory biomarker signature predicts incident tuberculosis and mortality in advanced human immunodeficiency virus[J]. Clin Infect Dis, 2020,71(10):2645-2654.
[26] Kalsdorf B, Scriba TJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria[J]. Am J Respir Crit Care Med, 2009,180(12):1262-1270.
[27] Suarez GV, Angerami MT, Vecchione MB, et al. HIV-TB coinfection impairs CD8(+) T-cell differentiation and function while dehydroepiandrosterone improves cytotoxic antitubercular immune responses[J]. Eur J Immunol, 2015,45(9):2529-2541.
[28] de Martino M, Lodi L, Galli L, et al. Immune response to Mycobacterium tuberculosis: a narrative review[J]. Front Pediatr, 2019,7:350.
[29] Mancino G, Placido R, Bach S, et al. Infection of human monocytes with Mycobacterium tuberculosis enhances human immunodeficiency virus type 1 replication and transmission to T cells[J]. J Infect Dis, 1997,175(6):1531-1535.
[30] Sáez-Cirión A, Manel N. Immune responses to retroviruses[J]. Annu Rev Immunol, 2018,36:193-220.
[31] Fenwick C, Joo V, Jacquier P, et al. T-cell exhaustion in HIV infection[J]. Annu Rev Immunol, 2018,36:193-220.
[32] Geldmacher C, Ngwenyama N, Schuetz A, et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection[J]. J Exp Med, 2010,207(13):2869-2881.
[33] de Noronha AL, Báfica A, Nogueira L, et al. Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infec-ted patients display decreased in situ TNF production[J]. Pathol Res Pract, 2008,204(3):155-161.
[34] Westendorp MO, Shatrov VA, Schulze-Osthoff K, et al. HIV-1 tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state[J]. EMBO J, 1995,14(3):546-554.
[35] Devalraju KP, Neela VSK, Ramaseri SS, et al. IL-17 and IL-22 production in HIV+ individuals with latent and active tuberculosis[J]. BMC Infect Dis, 2018,18(1):321.
[36] Bandaru A, Devalraju KP, Paidipally P, et al. Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection[J]. Eur J Immunol, 2014,44(7):2013-2024.
[37] Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection[J]. J Exp Med, 2006,203(10):2281-2292.
[38] Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions[J]. Annu Rev Immunol, 2009,27:551-589.
[39] Kisuya J, Chemtai A, Raballah E, et al. The diagnostic accuracy of Th1(IFN-γ, TNF-α, and IL-2) and Th2 (IL-4, IL-6 and IL-10) cytokines response in AFB microscopy smear negative PTB- HIV co-infected patients[J]. Sci Rep, 2019,9(1):2966.
[40] Bozzano F, Marras F, de Maria A. Immunology of tuberculosis[J]. Mediterr J Hematol Infect Dis, 2014,6(1):e2014027.
[41] Amelio P, Portevin D, Hella J, et al. HIV infection functionally impairs Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses[J]. J Virol, 2019,93(5):e01728-e01718.
[42] 赵方, 刘晓宁, 程林, 等. SOCS3及相关细胞因子在HIV/TB双重感染者血清中表达水平的研究[J]. 中华实验和临床病毒学杂志, 2017,31(6):515-518.
[43] 傅雅静, 张子宁, 刘飞鹰, 等. 我国HIV/TB双重感染者血清细胞因子水平的研究[J]. 中国医科大学学报, 2014,43(3):196-200.
[44] Saharia KK, Petrovas C, Ferrando-Martinez S, et al. Tuberculosis therapy modifies the cytokine profile, maturation state, and expression of inhibitory molecules on Mycobacterium tuberculosis-specific CD4+ T-cells[J]. PLoS One, 2016,11(7):e0158262.
[45] Sutherland R, Yang H, Scriba TJ, et al. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART[J]. AIDS, 2006,20(6):821-829.
[46] Desalegn G, Tsegaye A, Gebreegziabiher D, et al. Enhanced IFN-γ, but not IL-2, response to Mycobacterium tuberculosis antigens in HIV/latent TB co-infected patients on long-term HAART[J]. BMC Immunol, 2019,20(1):35.
[47] Tan Q, Min R, Dai GQ, et al. Clinical and Immunological Effects of rhIL-2 Therapy in Eastern Chinese patients with multidrug-resistant tuberculosis[J]. Sci Rep, 2017,7(1):17854.
文章导航

/